IGC Pharma, Inc. (India Globalization Capital, Inc.) — FY2022 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended March 31, 2022, with comparisons to the year ended March 31, 2021; it is not a calendar-year 2021 fourth-quarter report. IGC operates Infrastructure and Life Sciences segments. Life Sciences includes cannabinoid wellness products and investigational Alzheimer’s drug development. The company’s common stock trades on NYSE American under IGC.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $397,000 | $898,000 |
| Gross profit / margin | $194,000 / 48% | $113,000 / 12% |
| Operating loss | $15.428 million | $8.724 million |
| Net loss | $15.016 million | $8.811 million |
| Basic and diluted loss per share | $0.30 | $0.21 |
| Cash used in operating activities | $7.462 million | $10.800 million |
| Cash and cash equivalents at year-end | $10.460 million | $14.548 million |
| Working capital at year-end | $12.670 million | $21.149 million |
Revenue fell 56%. Management attributed the decline to lower infrastructure activity amid COVID-19 restrictions and a shift away from low-margin hand sanitizer sales. Gross margin improved as the company emphasized branded products and white-label services, although revenue remained very small relative to operating expenses.
FY2022 SG&A was $13.292 million, up 68%, and R&D was $2.330 million, up 151%. Management cited approximately $5.3 million of one-time and non-cash items in SG&A, including a $1.7 million hemp inventory net-realizable-value adjustment, approximately $1.7 million provision related to inventory reported stolen at a vendor, an $833,000 facility impairment, approximately $475,000 in provisions for advances, and litigation settlement expense. The filing says adjusted SG&A, excluding the cited items, was approximately $500,000 lower year over year.
Operating cash outflow improved year over year, but cash declined by $4.088 million. Financing provided $4.142 million, primarily from approximately $4.1 million of net ATM equity proceeds. Investing used $742,000, including $535,000 for intellectual property and patent-related costs. Management stated that available cash, cash equivalents, and short-term liquidity arrangements should cover needs for the next 12 months, while also saying it would continue raising capital as able. Current liabilities were $2.441 million versus current assets of $15.111 million.
Total liabilities were $2.942 million; loans were approximately $147,000 in total, including a $144,000 long-term EIDL balance. The company reported no material long-term debt apart from disclosed obligations. Operating lease liabilities totaled $464,000. No income tax expense or benefit was recorded; deferred tax assets were fully offset by a valuation allowance.
Material changes and business developments
- Infrastructure revenue declined, and equipment rental revenue was minimal. FY2022 segment revenue was $37,000 Infrastructure and $359,000 Life Sciences; the reported segment totals do not sum exactly to consolidated revenue because of rounding.
- Life Sciences revenue included $316,000 from wellness and lifestyle products and $43,000 from white-label services. The company said its new Holief and Sunday Seltzer brands generated $287,000 in revenue.
- Inventory fell from $5.478 million to $3.548 million, including the $1.7 million hemp crop adjustment. The company also recorded a provision related to inventory reported stolen at a vendor and said it was pursuing compensation.
- Shares outstanding increased from 47.827 million to 51.054 million during the fiscal year. The company raised approximately $4.1 million net through its ATM program; further issuance could dilute shareholders.
- The company received forgiveness of its approximately $430,000 PPP loan in June 2021, recorded as other income.
Outlook, commentary, and risks
- IGC-AD1: The company reported completing its Phase 1 dose-escalation trial and submitting the clinical/statistical report to the FDA in December 2021. It reported no serious or life-threatening adverse events or deaths in that trial. The company described small-cohort changes in neuropsychiatric inventory scores, but these early findings do not establish efficacy. Its planned Phase 2 study targets agitation in Alzheimer’s dementia, is designed for 146 participants, and was expected to take 12–18 months, subject to enrollment, COVID-19, and other uncertainties. The filing provides no assurance of FDA approval.
- TGR-63: The company intends to investigate this preclinical Alzheimer’s candidate. It obtained exclusive global rights through an agreement with JNCASR whose outstanding items were completed May 10, 2022, after fiscal year-end. Further research and development are required.
- Spending and funding: Management expects R&D costs to increase as IGC-AD1 Phase 2 and TGR-63 preclinical work progress. The company has a history of losses and stated it may seek additional financing; equity financing may dilute shareholders.
- Operating and regulatory risks: COVID-19 caused restrictions, higher project costs, delayed hemp processing, and clinical-site delays. The company cited limited visibility on recovery in India and Hong Kong. FDA rules for CBD in food and beverages remain uncertain; cannabinoid regulation, clinical-trial execution, manufacturing, customer concentration, inventory recovery, foreign exchange, and access to capital are material risks.
- Legal matters: Shareholder class-action litigation was settled during FY2022 and was approved and dismissed after year-end. Separate Apogee litigation remained pending at March 31, 2022, involving claims the company disputes; the filing says the company intends to defend itself.
- Reporting controls: Management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2022. The auditor issued an unqualified opinion on the financial statements, identified no critical audit matters, and was not engaged to audit internal control.
Most important facts for investors to verify
- Whether cash and available financing can support operating losses, planned clinical trials, and other commitments; assess the company’s reliance on ATM share sales and resulting dilution.
- Phase 2 IGC-AD1 trial status, enrollment, regulatory interactions, timeline, funding needs, and the clinical significance of results from the much smaller Phase 1 study.
- Recoverability of the vendor-related inventory and advances, the status of compensation claims, and the basis for the hemp inventory valuation adjustment.
- Whether new Life Sciences brands and white-label services can produce sustained revenue and margins, given FY2022 consolidated revenue of only $397,000.
- Potential outcomes and financial effects of the remaining Apogee litigation, and whether any subsequent developments change the disclosed contingencies.